Temasek, Lake Bleu lead $156m Series C round for Chinese vaccine developer RecBio

Temasek, Lake Bleu lead $156m Series C round for Chinese vaccine developer RecBio

Photo by Diana Polekhina on Unsplash

14 June, 2021

Lake Bleu Capital Rec-Biotechnology RecBio Temasek Holdings vaccines

Printed by Unregistered user on Wed, 17 Dec 2025 15:48:29 GMT

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief

Subscribe to Newsletter

You may also like

Venture Capital

Sequoia China co-leads $188m round in Covid vaccine developer Stemirna

IFC mulls up to $200m loan for China's COVID-19 vaccine maker Fosun Pharma

Read more from Greater China

CICC to buy two smaller rivals as Beijing strives for industry consolidation

Warburg Pincus signs deal to invest in business service provider Acclime